Trisalus Life Sciences Inc. has announced the publication of clinical data from a single-center study evaluating its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization. This study, published in the Journal of the Endocrine Society, assesses the safety, feasibility, and early efficacy of Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav® Infusion System. The study involved 22 patients with symptomatic thyroid disease, resulting in 100% technical and clinical success and a 73% mean reduction in thyroid gland volume at six months without major complications. These findings mark an expansion of the company's technology applications beyond liver cancers, offering insights into new treatment options for thyroid disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。